BioCentury | Mar 24, 2008
Finance

Ebb & Flow Focus

...out of Novartis's Sandoz AG unit in January 2006, and the October 2006 spinout of Macroflux Corp....
BioCentury | Nov 17, 2007
Financial News

Zosano closes series B round

...series B round, bringing the total amount of funds raised to $90 million. Zosano (previously Macroflux...
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

...acquisitions and alliances. Its Twinject epinephrine auto-injector is approved for emergency anaphylaxis. Macroflux 10/10/2006 $75.00 Macroflux...
...acquisitions and alliances. Its Twinject epinephrine auto-injector is approved for emergency anaphylaxis. Macroflux 10/10/2006 $75.00 Macroflux...
BioCentury | Jun 4, 2007
Company News

Macroflux management update

Macroflux Corp. , Mountain View, Calif. Business: Drug delivery Hired: M. Cory Zwerling as president and CEO, former president of Bristol-Myers Squibb Co. 's Bristol-Myers Squibb Medical Imaging unit; he replaces interim CEO Judy Hemberger WIR...
BioCentury | Oct 16, 2006
Company News

Macroflux board of directors update

Macroflux Corp. , Mountain View, Calif. Business: Drug delivery Appointed: Jim Barrett, general partner at New Enterprise Associates; Mike Raab, a partner at New Enterprise; Justin Duckworth, investment advisor at HBM Partners AG; and Nomura Phase4...
BioCentury | Oct 16, 2006
Company News

J&J drug delivery news

...technology into Macroflux Corp. (Mountain View, Calif.). Alza will retain an undisclosed stake in the newco. Macroflux...
...to enter Phase II testing to treat severe osteoporosis by the first half of 2007. Macroflux...
...COO of Pharmion Corp , is Macroflux’s CEO. Peter Daddona, who was CSO of Alza’s Macroflux...
BioCentury | Oct 11, 2006
Company News

Alza spins out Macroflux

...Macroflux (Mountain View, Calif.). The newco will develop compounds using its Macroflux transdermal delivery technology. Macroflux...
...The product is expected to enter Phase II testing by the first half of 2007. Macroflux...
...Pharmion (PHRM), is CEO of the newco; and Peter Daddona, who was CSO of Alza's Macroflux...
BioCentury | May 10, 2004
Clinical News

ThPTH: Phase I data

...Business: Musculoskeletal Molecular target: Parathyroid hormone (PTH) receptor Description: Transdermal formulation of parathyroid hormone using Macroflux...
BioCentury | Dec 22, 2003
Clinical News

ThPTH: Phase I

...Business: Musculoskeletal Molecular target: Parathyroid hormone receptor Description: Transdermal formulation of parathyroid hormone (PTH) using Macroflux...
BioCentury | Sep 30, 2002
Company News

Theratechnologies, J&J deal

...JNJ's Alza Corp. subsidiary will use its Macroflux technology to develop a transdermal formulation of a...
Items per page:
1 - 10 of 15
BioCentury | Mar 24, 2008
Finance

Ebb & Flow Focus

...out of Novartis's Sandoz AG unit in January 2006, and the October 2006 spinout of Macroflux Corp....
BioCentury | Nov 17, 2007
Financial News

Zosano closes series B round

...series B round, bringing the total amount of funds raised to $90 million. Zosano (previously Macroflux...
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

...acquisitions and alliances. Its Twinject epinephrine auto-injector is approved for emergency anaphylaxis. Macroflux 10/10/2006 $75.00 Macroflux...
...acquisitions and alliances. Its Twinject epinephrine auto-injector is approved for emergency anaphylaxis. Macroflux 10/10/2006 $75.00 Macroflux...
BioCentury | Jun 4, 2007
Company News

Macroflux management update

Macroflux Corp. , Mountain View, Calif. Business: Drug delivery Hired: M. Cory Zwerling as president and CEO, former president of Bristol-Myers Squibb Co. 's Bristol-Myers Squibb Medical Imaging unit; he replaces interim CEO Judy Hemberger WIR...
BioCentury | Oct 16, 2006
Company News

Macroflux board of directors update

Macroflux Corp. , Mountain View, Calif. Business: Drug delivery Appointed: Jim Barrett, general partner at New Enterprise Associates; Mike Raab, a partner at New Enterprise; Justin Duckworth, investment advisor at HBM Partners AG; and Nomura Phase4...
BioCentury | Oct 16, 2006
Company News

J&J drug delivery news

...technology into Macroflux Corp. (Mountain View, Calif.). Alza will retain an undisclosed stake in the newco. Macroflux...
...to enter Phase II testing to treat severe osteoporosis by the first half of 2007. Macroflux...
...COO of Pharmion Corp , is Macroflux’s CEO. Peter Daddona, who was CSO of Alza’s Macroflux...
BioCentury | Oct 11, 2006
Company News

Alza spins out Macroflux

...Macroflux (Mountain View, Calif.). The newco will develop compounds using its Macroflux transdermal delivery technology. Macroflux...
...The product is expected to enter Phase II testing by the first half of 2007. Macroflux...
...Pharmion (PHRM), is CEO of the newco; and Peter Daddona, who was CSO of Alza's Macroflux...
BioCentury | May 10, 2004
Clinical News

ThPTH: Phase I data

...Business: Musculoskeletal Molecular target: Parathyroid hormone (PTH) receptor Description: Transdermal formulation of parathyroid hormone using Macroflux...
BioCentury | Dec 22, 2003
Clinical News

ThPTH: Phase I

...Business: Musculoskeletal Molecular target: Parathyroid hormone receptor Description: Transdermal formulation of parathyroid hormone (PTH) using Macroflux...
BioCentury | Sep 30, 2002
Company News

Theratechnologies, J&J deal

...JNJ's Alza Corp. subsidiary will use its Macroflux technology to develop a transdermal formulation of a...
Items per page:
1 - 10 of 15